OM173-αA (CAS: 58286-56-9)

C₁₇H₁₆O₆

• Antibiotic [1-3].
• Antimycoplasma [1, 3, 4].
• Antifungal compound [1, 3].
• Anti-malarial agent [5].
• Ras-competitive non-CAAX mimetic type farnesyltransferase (FTase) inhibitor [6].
• Potential anticancer compound. Inducer of antiproliferative effects in tumor cell lines [6-8].
• Selective DNA (cytosine-5)-methyltransferase 3B (DNMT3B) inhibitor [8].

1. Nanaomycins, new antibiotics produced by a strain of Streptomyces. I. Taxonomy, isolation, characterization and biological properties: H. Tanaka, et al.; J. Antibiot. 28, 860 (1975)
2. Nanomycins, new antibiotics produced by a strain of Streptomyces. II. Structure and biosynthesis: H. Tanaka, et al.; J. Antibiot. 28, 868 (1975)
3. Nanaomycins, new antibiotics produced by a strain of Streptomyces. III. A new component, nanaomycin C, and biological activities of nanaomycin derivatives: H. Tanaka, et al.; J. Antibiot. 28, 925 (1975)
4. OM-173, new nanaomycin-type antibiotics produced by a strain of Streptomyces. Taxonomy, production, isolation and biological properties: Y. Iway, et al.; J. Antibiot. 36, 1268 (1983)
5. Heme-dependent radical generation: possible involvement in antimalarial action of non-peroxide microbial metabolites, nanaomycin A and radicicol: Y. Tanaka, et al.; J. Antibiot. 52, 880 (1999)
6. UCF76 compounds, new inhibitors of farnesyltransferase produced by Streptomyces: M. Hara, et al.; J. Antibiot. 54, 182 (2001)
7. Total synthesis and development of bioactive natural products: T. Kuniaki; Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 84, 87 (2008)
8. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells: D. Kuck, et al.; Mol. Cancer Ther. 9, 3015 (2010)